SCHEMBL8575259

SCHEMBL8575259

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CC(C)(O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 2/20 0.68
GRIN1 Q05586 1/20 0.68
GRIN2B Q13224 1/20 0.68
CYP2D6 P10635 1/20 0.67
CYP2C19 P33261 1/20 0.67
INPP5D Q92835 1/20 0.66
CDC25A P30304 3/20 0.61
POLA1 P09884 1/20 0.60
NPC1L1 Q9UHC9 3/20 0.57
OSBP P22059 1/20 0.55
OSBP2 Q969R2 1/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
USP2 O75604 1/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
SRD5A1 P18405 3/20 0.54
SRD5A2 P31213 3/20 0.54
FNTA P49354 1/20 0.54
FNTB P49356 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18376473 1.00 GRIN2A (0.68) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL20390519 1.00 GRIN2A (0.68) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL25988189 0.94 GRIN2A (0.72) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL25988186 0.94 GRIN2A (0.72) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL23430466 0.92 GRIN2A (0.67) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL18374274 0.92 GRIN2A (0.67) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL21257681 0.92 GRIN2A (0.67) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL18374275 0.92 GRIN2A (0.67) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL18376878 0.91 GRIN2A (0.68) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19
SCHEMBL24709777 0.91 GRIN2A (0.68) GRIN2AGRIN1GRIN2BCYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637408-B2 Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2026-05-26 US disclosed
US-20260132353-A1 LIPID COMPRISING DOCOSAPENTAENOIC COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2026-05-14 US disclosed
US-12529007-B2 Lipid comprising docosapentaenoic COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2026-01-20 US disclosed
US-12421472-B2 Process for producing extracted lipid comprising docosahexaenoic acid COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION - (AU) 2025-09-23 US disclosed
US-20240084214-A1 LIPID COMPRISING POLYUNSATURATED FATTY ACIDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2024-03-14 US disclosed
US-20230416186-A1 LIPID COMPOSITIONS COMPRISING TRIACYLGLYCEROL WITH LONG-CHAIN POLYUNSATURATED FATTY ACIDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2023-12-28 US disclosed
US-11834621-B2 Lipid comprising polyunsaturated fatty acids Nuseed Global Innovation Ltd. (GB) 2023-12-05 US disclosed
US-11718577-B2 Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2023-08-08 US disclosed
US-20230219879-A1 LIPID COMPRISING DOCOSAPENTAENOIC COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2023-07-13 US disclosed
US-20220356414-A1 PROCESS FOR PRODUCING EXTRACTED LIPID COMPRISING DOCOSAHEXAENOIC ACID COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2022-11-10 US disclosed
US-20150045569-A1 LIPID COMPRISING POLYUNSATURATED FATTY ACIDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2015-02-12 US disclosed
US-8946460-B2 Process for producing polyunsaturated fatty acids in an esterified form COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2015-02-03 US disclosed
US-8816111-B2 Lipid comprising polyunsaturated fatty acids COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2014-08-26 US disclosed
US-20130338387-A1 PROCESS FOR PRODUCING ETHYL ESTERS OF POLYUNSATURATED FATTY ACIDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2013-12-19 US disclosed
WO-2013185184-A2 PRODUCTION OF LONG CHAIN POLYUNSATURATED FATTY ACIDS IN PLANT CELLS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2013-12-19 WO disclosed
US-20130338388-A1 LIPID COMPRISING POLYUNSATURATED FATTY ACIDS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2013-12-19 US disclosed
US-20130288318-A1 HIGH OLEIC ACID OILS GRAINS RESEARCH AND DEVELOPMENT CORPORATION (AU) 2013-10-31 US disclosed
WO-2013159149-A1 HIGH OLEIC ACID OILS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2013-10-31 WO disclosed
EP-0871451-A1 STANOL COMPOSITION AND THE USE THEREOF Raisio Benecol Ltd. (FI) 1998-10-21 EP disclosed
WO-1998006405-A1 STANOL COMPOSITION AND THE USE THEREOF RAISIO BENECOL LTD. (FI) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637408-B2 Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids SCD, ELOVL3, DAGLA GRIN2A 1092/4885GRIN1 1798/4885GRIN2B 3017/4885
US-12529007-B2 Lipid comprising docosapentaenoic DAGLA, SCD, FADS2 GRIN2A 2038/4885GRIN1 2206/4885GRIN2B 3828/4885
US-20260132353-A1 LIPID COMPRISING DOCOSAPENTAENOIC ELOVL3, SCD, ELOVL6 GRIN2A 2216/4885GRIN1 2261/4885GRIN2B 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.